Tuesday, July 15, 2025

Creating liberating content

Introducing deBridge Finance: Bridging...

In the dynamic landscape of decentralized finance (DeFi), innovation is a constant,...

Hyperliquid Airdrop: Everything You...

The Hyperliquid blockchain is redefining the crypto space with its lightning-fast Layer-1 technology,...

Unlock the Power of...

Join ArcInvest Today: Get $250 in Bitcoin and a 30% Deposit Bonus to...

Claim Your Hyperliquid Airdrop...

How to Claim Your Hyperliquid Airdrop: A Step-by-Step Guide to HYPE Tokens The Hyperliquid...
HomeSportsInfarmed banned the...

Infarmed banned the export of 140 drugs

According to an information circular that comes into force this Friday, the National Medicines Authority (Infarmed) has banned the export of 140 drugs of various categories and active substances.

The information circular issued by the national regulatory body updates the list of drugs whose exports are temporarily suspended, a list that is compiled monthly and includes drugs that were out of stock in the previous month and whose impact is assessed as medium or high.

Compared to November, the published list now has two fewer drugs, a total of 140 forms of drugs of various categories and active ingredients, such as methylphenidate (psychostimulant), chlorpromazine (antipsychotic), propranolol (hypotensive drug), meningococcal vaccine (Nimenrix), oxycodone . (opioid analgesic) or Japanese encephalitis vaccine (Ixiaro).

“This suspension aims to ensure the normalization of supplies of critical medicines that were out of stock in October, as well as medicines that are supplied under an exclusive use authorization,” the document published on the Infarmed website said.

Infarmed monitors information about shortages, gaps and discontinuations in order to promptly identify and avoid critical situations that could affect the availability of drugs.

The National Medicines Authority is part of a European network of contact points between competent national authorities, the European Medicines Agency (EMA) and the European Commission, which has been used since April 2019 to exchange information on supply disruptions and availability issues of authorized medicines. in the European Union.

Author: Lusa
Source: CM Jornal

Get notified whenever we post something new!

Continue reading